Catalyst Oncology recently partnered with a biotech sponsor to launch a global confirmatory trial for a rare ovarian cancer indication. Facing urgent timelines, complex regulatory requirements, and challenging patient recruitment, Catalyst Oncology leveraged data-driven site selection, deep therapeutic expertise, and close collaboration with cooperative groups to meet critical milestones and support FDA accelerated approval.
Download the case study “Accelerating Approval Pathway for Phase III Ovarian Cancer Trial” to learn how Catalyst Oncology’s flexible approach and global experience can help sponsors navigate accelerated approval pathways for ovarian cancer therapies.
